Table of Contents

company-logo

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Emergent BioSolutions Dividend Announcement

• Emergent BioSolutions does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Emergent BioSolutions dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Emergent BioSolutions Dividend History

Emergent BioSolutions Dividend Yield

Emergent BioSolutions current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Emergent BioSolutions stock? Use our calculator to estimate your expected dividend yield:

Emergent BioSolutions Financial Ratios

P/E ratio-2.23
PEG ratio-0.08
P/B ratio0.91
ROE-37.83%
Payout ratio0.00%
Current ratio2.88
Quick ratio1.47
Cash Ratio0.65

Emergent BioSolutions Dividend FAQ

Does Emergent BioSolutions stock pay dividends?
Emergent BioSolutions does not currently pay dividends to its shareholders.
Has Emergent BioSolutions ever paid a dividend?
No, Emergent BioSolutions has no a history of paying dividends to its shareholders. Emergent BioSolutions is not known for its dividend payments.
Why doesn't Emergent BioSolutions pay dividends?
There are several potential reasons why Emergent BioSolutions would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Emergent BioSolutions ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Emergent BioSolutions has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Emergent BioSolutions a dividend aristocrat?
Emergent BioSolutions is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Emergent BioSolutions a dividend king?
Emergent BioSolutions is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Emergent BioSolutions a dividend stock?
No, Emergent BioSolutions is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Emergent BioSolutions stocks?
To buy Emergent BioSolutions you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Emergent BioSolutions stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.